Search

Your search keyword '"Murasawa, Hiroyasu"' showing total 30 results
Start Over Author "Murasawa, Hiroyasu"
30 results on '"Murasawa, Hiroyasu"'

10. Evaluation of cognitive function in diabetic germ-free mice

Author

Kobayashi, Hiroyuki, primary, Murasawa, Hiroyasu, additional, Pawlak, Akiko, additional, Katayama, Kazutaka, additional, Kishigai, Daisuke, additional, Shimato, Saki, additional, Sugiyama, Miki, additional, Okuyama, Masae, additional, Imaizumi, Takahito, additional, Shimato, Nozomu, additional, Nonomura, Hiroko, additional, Nishiyama, Ryusei, additional, Mizuki, Takuji, additional, and Hirasawa, Yasushi, additional

Published
2021
Full Text
View/download PDF

19. Dehydroeffusol Rescues Amyloid β25-35-Induced Spatial Working Memory Deficit.

Author

Fukuda, Toshiyuki, Sato, Yuichi, Takiguchi, Mako, Yamamoto, Takahiro, Murasawa, Hiroyasu, Pawlak, Akiko, Kobayashi, Hiroyuki, Tamano, Haruna, and Takeda, Atsushi

Subjects
AMYLOID beta-protein precursor, SHORT-term memory, MEMBRANE proteins, ALZHEIMER'S disease prevention, CHINESE medicine, JUNCUS effusus, BIOLOGICAL models, ALZHEIMER'S disease, ANIMAL experimentation, HYDROCARBONS, LEARNING, MEMORY disorders, MICE, PEPTIDES, ANIMALS
Abstract

Amyloid β (Aβ) peptides produced from the amyloid precursor protein, a transmembrane protein, are neurotoxic and blocking the neurotoxicity may lead to prevention of Alzheimer's disease (AD). Here we tested whether Aβ25-35-induced cognitive decline is rescued by treatment with dehydroeffusol, a phenanthrene isolated from Chinese medicine Juncus effusus. Dehydroeffusol (5 ~ 15 mg/kg body weight) was orally administered to mice for 6 days and Aβ25-35 (2 mM) was injected at the rate of 1 μl/min for 3 min into the lateral ventricle. Y-maze test was performed after dehydroeffusol administration for 12 days. Aβ25-35 impaired learning and memory in the test, while the impairment was dose-dependently rescued by dehydroeffusol administration. The present study indicates that treatment with dehydroeffusol is effective for rescuing Aβ25-35-induced cognitive decline. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

21. Novel oestrogen receptor β-selective ligand reduces obesity and depressive-like behaviour in ovariectomized mice

Author

Sasayama, Daimei, primary, Sugiyama, Nobuhiro, additional, Yonekubo, Shigeru, additional, Pawlak, Akiko, additional, Murasawa, Hiroyasu, additional, Nakamura, Mie, additional, Hayashi, Morimichi, additional, Ogawa, Takashi, additional, Moro, Makoto, additional, Washizuka, Shinsuke, additional, Amano, Naoji, additional, Hongo, Kazuhiro, additional, and Ohnota, Hideki, additional

Published
2017
Full Text
View/download PDF

22. Novel oestrogen receptor beta-selective ligand reduces obesity and depressive-like behaviour in ovariectomized mice

Author

Sasayama, Daimei, Sugiyama, Nobuhiro, Yonekubo, Shigeru, Pawlak, Akiko, Murasawa, Hiroyasu, Nakamura, Mie, Hayashi, Morimichi, Ogawa, Takashi, Moro, Makoto, Washizuka, Shinsuke, Amano, Naoji, Hongo, Kazuhiro, and Ohnota, Hideki

Abstract

Hormonal changes due to menopause can cause various health problems including weight gain and depressive symptoms. Multiple lines of evidence indicate that oestrogen receptors (ERs) play a major role in postmenopausal obesity and depression. However, little is known regarding the ER subtype-specific effects on obesity and depressive symptoms. To delineate potential effects of ER beta activation in postmenopausal women, we investigated the effects of a novel oestrogen receptor beta-selective ligand (C-1) in ovariectomized mice. Uterine weight, depressive behaviour, and weight gain were examined in sham-operated control mice and ovariectomized mice administered placebo, C-1, or 17 beta-oestradiol (E2). Administration of C-1 or E2 reduced body weight gain and depressive-like behaviour in ovariectomized mice, as assessed by the forced swim test. In addition, administration of E2 to ovariectomized mice increased uterine weight, but administration of C-1 did not result in a significant increase in uterine weight. These results suggest that the selective activation of ERa in ovariectomized mice may have protective effects against obesity and depressive-like behaviour without causing an increase in uterine weight. The present findings raise the possibility of the application of ER beta-ligands such as C-1 as a novel treatment for obesity and depression in postmenopausal women., Article, SCIENTIFIC REPORTS. 7:4663 (2017)

Published
2017

23. Antidepressant-like effects of the delta-opioid receptor agonist SNC80 ([(+)-4-[(alphaR)-alpha-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide) in an olfactory bulbectomized rat model

Author

Saitoh, Akiyoshi, primary, Yamada, Mitsuhiko, additional, Yamada, Misa, additional, Takahashi, Kou, additional, Yamaguchi, Kazumasa, additional, Murasawa, Hiroyasu, additional, Nakatani, Akiko, additional, Tatsumi, Yoshimi, additional, Hirose, Noritaka, additional, and Kamei, Junzo, additional

Published
2008
Full Text
View/download PDF

25. Folia Pharmacologica Japonica

Author

Yamaguchi, Kazumasa, primary, Nakatani, Akiko, additional, Murasawa, Hiroyasu, additional, Fujimura, Kyoko, additional, Tatsumi, Yoshimi, additional, and Tatsumi, Morio, additional

Published
2006
Full Text
View/download PDF

29. [Update on the animal models of schizophrenia].

Author

Yamaguchi K, Nakatani A, Murasawa H, Fujimura K, Tatsumi Y, and Tatsumi M

Subjects
Animals, Behavior, Animal, Brain pathology, Drug Design, Excitatory Amino Acid Antagonists, Glycine, Humans, Phencyclidine, Receptors, N-Methyl-D-Aspartate antagonists & inhibitors, Serine, Disease Models, Animal, Schizophrenia etiology, Schizophrenia pathology, Schizophrenia physiopathology
Published
2006
Full Text
View/download PDF

30. [The approaches in the discovery of antidepressants using affective disorder models].

Author

Saitoh A, Yamaguchi K, Murasawa H, and Kamei J

Subjects
Animals, Humans, Male, Mice, Mood Disorders etiology, Rats, Rats, Wistar, Antidepressive Agents therapeutic use, Conditioning, Psychological, Disease Models, Animal, Drug Design, Mood Disorders drug therapy, Olfactory Bulb surgery
Abstract

With the recent appearance of SSRI and SNRI, medication options with respect to depression have broadened. However, patients displaying clear improvement with existing antidepressants still do not exceed about 60 percent of total patients. New types of therapeutic agent development are currently required. Conditions for the determination of new antidepressants are: 1) instantaneous medications displaying a high level of antidepressant action in the early stages of treatment and 2) medications displaying efficacy with respect to patients that are therapy-resistant. However, drug discovery using new animal models is critical as part of drug development of these types of antidepressants in addition to models used in the past such as the forced swim test. We adopted two animal models (olfactory bulbectomy model and conditioned fear stress (CFS) model) developed for pharmacological evaluation of antidepressants. It has been well known that olfactory bulbectomied rats display extreme emotional response (aggressiveness and anxiety). However the improvement of this response occurs following chronic but not acute antidepressant treatment. Thus, we used this model to evaluate the period of the manifestation of antidepressant action. Mice exhibited a marked suppression of motility when they were returned to the same environment in which they had previously received an electric foot shock. Thus, it is suggested that the CFS stress model may be a useful model for therapy-resistant depression due to the fact that motor suppression is not readily attenuated by antidepressant treatment. In this report, we provide an overview of the approaches in the discovery of new antidepressants using these affective disorder models.

Published
2003

Catalog

Books, media, physical & digital resources
See catalog results